Skip to main content
. 2023 May 21;15:17588359231169983. doi: 10.1177/17588359231169983

Figure 3.

Figure 3.

Probabilistic sensitivity analysis. (a) Cost-effectiveness acceptable curves show the cost-effective probabilities of T-DXd at different WTP thresholds. The dark dotted lines represent the WTP thresholds. (b) Scatterplot of 10,000 Monte Carlo simulations shows low probability of cost-effectiveness.

QALY, quality-adjusted life-year; T-DXd, trastuzumab deruxtecan; WTP, willingness-to-pay.